<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37813597</PMID><DateCompleted><Year>2023</Year><Month>10</Month><Day>16</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>26</Day></DateRevised><Article PubModel="Electronic-Print"><Journal><ISSN IssnType="Electronic">2332-7812</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Neurology(R) neuroimmunology &amp; neuroinflammation</Title><ISOAbbreviation>Neurol Neuroimmunol Neuroinflamm</ISOAbbreviation></Journal><ArticleTitle>Chronic Enterovirus Meningoencephalitis in Prolonged B-Cell Depletion After Rituximab Therapy: Case Report.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e200171</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1212/NXI.0000000000200171</ELocationID><Abstract><AbstractText Label="OBJECTIVES">Persistent impaired immunity is possible even years after B-cell depleting therapies. This may favor the occurrence of infections, including infectious meningitis and encephalitis. In this study, we report a case of chronic enterovirus meningoencephalitis in prolonged B-cell depletion years after rituximab therapy.</AbstractText><AbstractText Label="METHODS">This is a case report from a German academic hospital. In addition to repeated clinical examinations, repeated brain MRI and extended CSF and laboratory diagnostics were performed. We used the CARE checklist when writing our report.</AbstractText><AbstractText Label="RESULTS">A 38-year-old man presented with high fever (&gt;40°C), severe headache, and progressive neurologic and cognitive deficits. As result of previous lymphoma therapy with rituximab years ago, prolonged B-cell aplasia was detected. To restore humoral immunity, the patient received repeated infusions of immunoglobulins. In the end, a complete restitution of the physical and mental condition was achieved with the established therapy.</AbstractText><AbstractText Label="DISCUSSION">This case report should emphasize the importance of assessing humoral immunity even years after B-cell depletion therapy, especially in case of opportunistic infections.</AbstractText><CopyrightInformation>Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jacksch</LastName><ForeName>Clemens</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>From the Klinik für Neurologie (C.J., F.L., K.S., D.B., E.S.); Institut für Klinische Chemie (J.D., F.L.), Universitätsklinikum Schleswig-Holstein, Kiel/Lübeck; and Robert Koch Institut (S.B., S.D.), Nationales Referenzzentrum für Poliomyelitis und Enteroviren, Berlin, Deutschland. clemensjacksch@googlemail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dargvainiene</LastName><ForeName>Justina</ForeName><Initials>J</Initials><Identifier Source="ORCID">0009-0002-4114-3748</Identifier><AffiliationInfo><Affiliation>From the Klinik für Neurologie (C.J., F.L., K.S., D.B., E.S.); Institut für Klinische Chemie (J.D., F.L.), Universitätsklinikum Schleswig-Holstein, Kiel/Lübeck; and Robert Koch Institut (S.B., S.D.), Nationales Referenzzentrum für Poliomyelitis und Enteroviren, Berlin, Deutschland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Böttcher</LastName><ForeName>Sindy</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>From the Klinik für Neurologie (C.J., F.L., K.S., D.B., E.S.); Institut für Klinische Chemie (J.D., F.L.), Universitätsklinikum Schleswig-Holstein, Kiel/Lübeck; and Robert Koch Institut (S.B., S.D.), Nationales Referenzzentrum für Poliomyelitis und Enteroviren, Berlin, Deutschland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diedrich</LastName><ForeName>Sabine</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>From the Klinik für Neurologie (C.J., F.L., K.S., D.B., E.S.); Institut für Klinische Chemie (J.D., F.L.), Universitätsklinikum Schleswig-Holstein, Kiel/Lübeck; and Robert Koch Institut (S.B., S.D.), Nationales Referenzzentrum für Poliomyelitis und Enteroviren, Berlin, Deutschland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leypoldt</LastName><ForeName>Frank</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-8972-515X</Identifier><AffiliationInfo><Affiliation>From the Klinik für Neurologie (C.J., F.L., K.S., D.B., E.S.); Institut für Klinische Chemie (J.D., F.L.), Universitätsklinikum Schleswig-Holstein, Kiel/Lübeck; and Robert Koch Institut (S.B., S.D.), Nationales Referenzzentrum für Poliomyelitis und Enteroviren, Berlin, Deutschland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stürner</LastName><ForeName>Klarissa</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>From the Klinik für Neurologie (C.J., F.L., K.S., D.B., E.S.); Institut für Klinische Chemie (J.D., F.L.), Universitätsklinikum Schleswig-Holstein, Kiel/Lübeck; and Robert Koch Institut (S.B., S.D.), Nationales Referenzzentrum für Poliomyelitis und Enteroviren, Berlin, Deutschland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berg</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>From the Klinik für Neurologie (C.J., F.L., K.S., D.B., E.S.); Institut für Klinische Chemie (J.D., F.L.), Universitätsklinikum Schleswig-Holstein, Kiel/Lübeck; and Robert Koch Institut (S.B., S.D.), Nationales Referenzzentrum für Poliomyelitis und Enteroviren, Berlin, Deutschland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schäffer</LastName><ForeName>Eva</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>From the Klinik für Neurologie (C.J., F.L., K.S., D.B., E.S.); Institut für Klinische Chemie (J.D., F.L.), Universitätsklinikum Schleswig-Holstein, Kiel/Lübeck; and Robert Koch Institut (S.B., S.D.), Nationales Referenzzentrum für Poliomyelitis und Enteroviren, Berlin, Deutschland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurol Neuroimmunol Neuroinflamm</MedlineTA><NlmUniqueID>101636388</NlmUniqueID><ISSNLinking>2332-7812</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>4F4X42SYQ6</RegistryNumber><NameOfSubstance UI="D000069283">Rituximab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069283" MajorTopicYN="N">Rituximab</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="Y">Enterovirus Infections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008590" MajorTopicYN="Y">Meningoencephalitis</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001402" MajorTopicYN="N">B-Lymphocytes</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors report no relevant disclosures. Go to Neurology.org/NN for full disclosures.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>6</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>16</Day><Hour>6</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>14</Day><Hour>10</Hour><Minute>49</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>9</Day><Hour>21</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>10</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37813597</ArticleId><ArticleId IdType="pmc">PMC10574820</ArticleId><ArticleId IdType="doi">10.1212/NXI.0000000000200171</ArticleId><ArticleId IdType="pii">10/6/e200171</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gagnier JJ, Kienle G, Altman DG, et al. . The CARE guidelines: consensus-based clinical case reporting guideline development. BMJ Case Rep. 2013;2013:bcr2013201554. doi:10.1136/bcr-2013-201554</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bcr-2013-201554</ArticleId><ArticleId IdType="pmc">PMC3844611</ArticleId><ArticleId IdType="pubmed">24228906</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoelzer D, Walewski J, Serve H, et al. . Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial. Blood. 2014;124(26):3870-3879. doi:10.1182/blood-2014-03-563627</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2014-03-563627</ArticleId><ArticleId IdType="pmc">PMC4271177</ArticleId><ArticleId IdType="pubmed">25359988</ArticleId></ArticleIdList></Reference><Reference><Citation>Esposito S, Principi N. Hand, foot and mouth disease: current knowledge on clinical manifestations, epidemiology, aetiology and prevention. Eur J Clin Microbiol Infect Dis. 2018;37(3):391-398. doi:10.1007/s10096-018-3206-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10096-018-3206-x</ArticleId><ArticleId IdType="pubmed">29411190</ArticleId></ArticleIdList></Reference><Reference><Citation>Ribrag V, Koscielny S, Bosq J, et al. . Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387(10036):2402-2411. doi:10.1016/S0140-6736(15)01317-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(15)01317-3</ArticleId><ArticleId IdType="pubmed">27080498</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiel J, Rizzi M, Engesser M, et al. . B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients. Arthritis Res Ther. 2017;19(1):101. doi:10.1186/s13075-017-1306-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-017-1306-0</ArticleId><ArticleId IdType="pmc">PMC5437549</ArticleId><ArticleId IdType="pubmed">28521808</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith KGC, Jones RB, Burns SM, Jayne DRW. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum. 2006;54(9):2970-2982. doi:10.1002/art.22046</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.22046</ArticleId><ArticleId IdType="pubmed">16947528</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplan B, Kopyltsova Y, Khokhar A, Lam F, Bonagura V. Rituximab and immune deficiency: case series and review of the literature. J Allergy Clin Immunol Pract. 2014;2(5):594-600. doi:10.1016/j.jaip.2014.06.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaip.2014.06.003</ArticleId><ArticleId IdType="pubmed">25213054</ArticleId></ArticleIdList></Reference><Reference><Citation>Tellez R, Lastinger AM, Hogg JP. Chronic enteroviral meningoencephalitis in a patient on rituximab for the treatment of psoriatic arthritis: a case report and brief literature review. IDCases. 2019;17:e00558. doi:10.1016/j.idcr.2019.e00558</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.idcr.2019.e00558</ArticleId><ArticleId IdType="pmc">PMC6522838</ArticleId><ArticleId IdType="pubmed">31193253</ArticleId></ArticleIdList></Reference><Reference><Citation>Grisariu S, Vaxman I, Gatt M, et al. . Enteroviral infection in patients treated with rituximab for non-Hodgkin lymphoma: a case series and review of the literature: enteroviral infection in patients treated with rituximab. Hematolo Oncol. 2017;35(4):591-598. doi:10.1002/hon.2365</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hon.2365</ArticleId><ArticleId IdType="pubmed">27734521</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>